CLS laser therapy study reports median survival of 14 months in recurrent glioblastoma

• CLS highlighted published trial results supporting the safety of its ClearPoint PRISM non-cooled laser system for aggressive brain tumors.
• The phase 1 study included 14 patients with recurrent or newly diagnosed glioblastoma or grade 4 astrocytoma.
• Preliminary findings suggested MRI-guided laser treatment was at least as effective as open surgery for recurrent glioblastoma; long-term monitoring continues.
• Most neurological complications were temporary; none were serious. Most patients left the hospital two days following treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CLS - Clinical Laserthermia Systems AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.